Original Article

Low KCNQ1 expression is associated with unfavorable outcome and metabolism of gastric cancer

Zhenyu Yang1*, Sensen Duan1*, Xi'e Hu1*, Baishu Dai2, Guoqiang Bao1, Wei Xin1

1Department of General Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi’an 710038, Shaanxi, China; 291918 Unit Health Center of Chinese People’s Liberation Army, Beijing 100007, China. *Equal contributors.

Received March 14, 2023; Accepted May 12, 2023; Epub June 15, 2023; Published June 30, 2023

Abstract: Background: Potassium voltage-gated channel subfamily Q member 1 (KCNQ1), is implicated in the onset and progression of gastric carcinoma (GC), one of the most common types of stomach malignancies. This research aims to investigate the potential prognostic implications of KCNQ1 mRNA in GC using various databases such as The Cancer Genome Atlas (TCGA), The Human Protein Atlas (HPA), LinkedOmics, TISIDB, ESTIMATE, and TIMER.

Methods: We searched the HPA database to obtain information on KCNQ1 levels in human normal tissues, organs, and cell lines as well as in pan-cancer tissues. Then, we used TIMER and UALCAN to comparatively analyze the KCNQ1 mRNA levels in different types of cancers relative to their adjacent normal counterparts. Based on TCGA and Gene Expression Omnibus, the correlation of clinical information with KCNQ1 expression was analyzed using logistic regression model. Univariable and Multivariate Cox analyses were then carried out to compare differences in survival among patients with different clinical characteristics. The multivariate methods, such as Kaplan-Meier plotter and GEPIA survival curves, were further employed to identify the correlation of KCNQ1 expression with overall survival (OS). Besides, LinkedOmics was used to identify differentially expressed genes for functional enrichment analysis. Results: KCNQ1 exhibited tissue-specific imprinting and expression in human normal tissues, organs and cell lines, while it was aberrantly expressed in pan-cancer tissues. Lower KCNQ1 mRNA expression was determined in GC tissue samples versus normal counterparts. In GC cases, elevated KCNQ1 levels were strongly linked to a longer OS and strongly correlated with invasion depth ($\chi^2=12.631$, $P=0.006$), TNM stage ($\chi^2=8.750$, $P=0.033$), differentiation grade ($\chi^2=7.426$, $P=0.024$), and vital status ($\chi^2=5.676$, $P=0.017$). Furthermore, KCNQ1 was identified by univariable and multivariate Cox analyses as an independent risk factor for GC. Based on Gene Ontology analysis, digestion as well as tricarboxylic acid metabolic, carbohydrate catabolic, and small molecule catabolic processes were differentially enriched in the up-regulated KCNQ1 phenotypic pathway. While carbon metabolism, fatty acid degradation, peroxisome, and citrate cycle (TCA cycle) were identified by the Kyoto Encyclopedia of Genes and Genomes-based analysis as pathways with differential enrichment. Conclusion: Being a prognostic biomarker, KCNQ1 may play an inhibitory role and involve in the metabolic process of GC.

Keywords: KCNQ1, gastric carcinoma (GC), TCGA, bioinformatics, prognosis, metabolic process

Introduction

Gastric carcinoma (GC), a high-incidence gastrointestinal malignancy, is the third leading cause of cancer-related deaths worldwide [1]. Despite continuous progresses in cancer-related therapies, the outcomes of GC patients remain unsatisfactory, partially due to the unclear pathogenesis, lack of effective prognostic markers, and late diagnosis in most patients. Meanwhile, given the heterogeneity of GC [2, 3], it is challenging to fully elucidate the different prognoses or therapeutic responses of GC based on microsatellite instability (MSI), HER2 mutation, and amplification [4, 5]. Traditional standard chemotherapy and targeted therapy based on precision medicine played an insufficient role in enhancing the overall survival (OS) of GC patients [6]. In recent years, immunotherapy (IT), as a novel therapeutic approach for most malignant tumors, has been widely applied as the first-line treatment for GC. However, nearly all patients eventually experience disease progression due to drug-induced
Low KCNQ1 expression and gastric cancer

immune escape or resistance in the immune microenvironment [7, 8]. Tumor mutation burden and MSI are considered to be key factors in predicting the response of IT [9, 10]. In addition, key genes driving immune response can be considered as therapeutic targets and effective indicators [11]. Therefore, it is necessary to identify additional reliable indicators and biomarkers to predict the prognosis of GC patients undergoing IT.

Potassium voltage-gated channel subfamily Q member 1 (KCNQ1) is a protein coding gene that encodes voltage-gated potassium channels (VGPCs) required for the repolarization phase of cardiac action potential. It is widely expressed in various tissues, including the heart, inner ear, stomach, colon, and others [11-14]. Exhibiting tissue-specific imprinting, this gene is preferentially expressed from maternal allele in certain tissues and shows biallelic expression in others [15]. KCNQ1 mutations are associated with many diseases, including deafness, diabetes mellitus, Jervell and Lange-Nielsen Syndrome 1, long QT syndrome 1, and familial atrial fibrillation, as well as pathways involved in chemical synapse transmission and circadian entrainment. The annotations of KCNQ1 based on Gene Ontology (GO) are calmodulin and ion channel binding, with KCNQ5 being its important paralog. Aberrantly expressed K+ channels in human cancers have been previously reported [16, 17]. For instance, KCNQ1 has been shown to be an antioncogene in mouse and human colorectal carcinoma [18], and hypermethylated KCNQ1 plays a tumor-inhibiting role in hepatocellular carcinoma (HCC) [19]. However, there is limited research on the functional and molecular events linking KCNQ1 to GC.

Herein, we comprehensively analyzed KCNQ1 levels in pan-cancers and its correlations with the clinicopathological features of GC patients. In addition, the association between KCNQ1 differential expression and prognosis as well as the co-expression interaction (CEI) networks in GC were investigated using sequencing data sets. This study aimed to reveal the prognostic implications of KCNQ1 expression in pan-cancers and its potential role as a prognostic indicator, so that we can have a better understanding of GC progression and treatment resistance mechanisms.

Methods

Gene expression profiles and clinical features in databases

Data were retrieved from The Cancer Genome Atlas (TCGA) database (URL: https://genome-cancer.ucsc.edu/), which provides clinic and pathological information on 33 tumor types. The Human Protein Atlas (HPA) project can support proteome analysis based on 26941 antibodies against 17165 unique proteins, from which we collected information on KCNQ1 mRNA levels of normal human tissues, organs and cell lines. Differences in KCNQ1 mRNA between human pan-cancers and the adjacent counterparts were also identified by TIMER (URL: http://cistrome.org/TIMER/) and UALCAN (URL: http://ualcan.path.uab.edu/) as well as the xiantao.love platform (URL: https://www.xiantao.love/products). We collected clinicopathological details and general information of GC cases from the TCGA and GEO based on KCNQ1 expression profiling, and discussed its correlation with clinicopathological characteristics. Quantitative variables, statistically displayed as the mean ± SD, were analyzed using unpaired t-test. Fisher’s exact or Pearson chi-square test was employed to determine the connection between KCNQ1 and clinical characteristics.

Survival and statistical analyses

Patients were categorized as either high or low KCNQ1 expression group based on the median. We used Kaplan-Meier (KM) plotter (URL: http://kmplot.com/analysis/) to evaluate the impact of individual genes on the survival of patients with GC or other cancers. GEPIA [20] (URL: http://gepia.cancer-pku.cn/), a web-based instrument with a standard processing pipeline, was utilized to analyze the data retrieved from TCGA and genotype-tissue expression. The correlation of KCNQ1 with OS of GC patients was evaluated using KM plotter for GEO data and GEPIA for TCGA data, respectively. Furthermore, we calculated the P-values as well as hazard ratios (HRs) with 95% confidence intervals (CIs) using log-rank tests. A logistic regression analysis was then conducted to identify the association of the clinical characteristics with KCNQ1 expression in different groups. Whether the KCNQ1 gene is an inde-
pendent prognostic factor for GC survival was determined using multivariate Cox analysis. A minimum significance level of \( P \)-value less than 0.05 was set. The aforementioned analytical methods and the R package were utilized with the R software v4.0.3 (The R Foundation for Statistical Computing Platform, 2020).

**CEI and protein-protein interaction (PPI) network analysis**

Thirty-two cancer-related multidimensional TCGA datasets were analyzed using LinkedOmics (URL: http://www.linkedomics.org/login.php) [21], in which the Link-Finder module was used to identify KCNQ1-related differentially expressed genes in GC in TCGA-STAD that were activated between high and low KCNQ1 level datasets. Correlations were tested by Pearson correlation coefficients, which are presented in volcano plots and heatmaps. We conducted enrichment analysis using the LinkInterpreter module to identify relevant pathways in both groups, such as Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and GO biological processes enriched by the top ranked genes. We used STRING database (URL: https://www.string-db.org/) to identify and build PPI networks and SWISS-MODEL (URL: https://swissmodel.expasy.org) [21] to model KCNQ1 protein homology based on its primary sequence.

**Results**

**KCNQ1 expression in normal human tissues and organs**

Exhibiting tissue-specific imprinting, KCNQ1 was preferentially expressed in heart, inner ear, pancreas, prostate, kidneys, stomach, small intestine, and peripheral blood white blood cells. It’s also named as calmodulin binding protein, as well as voltage gated, ion, and potassium channel, with potassium transport as its main function. The HPA database provided information on KCNQ1 mRNA expression in various tissues, revealing its specific enhancement in the adrenal gland, ductus deferens, and seminal vesicle. However, the expression of KCNQ1 in human brain showed low regional specificity (Figure 1A). The genome-wide differential analysis of cell type specific protein-coding genes indicated that KCNQ1 mRNA expression was notably enhanced in undifferentiated cells and enterocytes (Figure 1B) and was detected in various blood and immune cells, but exhibited low cell type specificity in these cells (Figure 1C). Among KCNQ1-expressing cell lines, KCNQ1 mRNA was especially enhanced in HMC-1, OE19, RPMI-8226, U-937, and U-266/70 (Figure 1D). Protein expression analysis showed that KCNQ1 protein was mainly expressed in the cytoplasm and membrane of the adrenal and thyroid glands, as well as the stomach.

**KCNQ1 mRNA differs between human pancarcinomatous tissues and adjacent counterparts**

KCNQ1 mRNA expression was compared between diverse pancarcinomatous tissues and paracancerous counterparts in different databases, including HPA, TIMER and UALCAN. We assessed KCNQ1 levels in pancarcinomas using the HPA database and found its moderate cytoplasmic and membranous positivity in thyroid colorectal and carcinomas and in a small number of melanomas, ovarian, stomach, pancreatic and liver carcinomas, but it was weakly stained or negative in the remaining cancers (Figure 2A). KCNQ1-negative was found in most tumor cells, with only varying levels of cytoplasmic and membranous immunoreactivity seen in colorectal and stomach carcinoma cells (Figure 2B). According to the analysis results of the TIMER database, KCNQ1 was found to be significantly downregulated in breast invasive carcinoma, kidney renal papillary cell carcinoma, lung squamous cell carcinoma, thyroid carcinoma, lung adenocarcinoma, HCC, prostate adenocarcinoma, skin cutaneous melanoma, and stomach adenocarcinoma (STAD) in comparison to their corresponding control tissues. By contrast, it showed significantly elevated levels in cholangiocarcinoma, colon adenocarcinoma, kidney clear cell carcinoma, head and neck cancer, kidney chromophobe, and rectum adenocarcinoma than those in adjacent counterparts (Figure 2C). Further, we assessed KCNQ1 expression in pancarcinomas using UALCAN data and xiantao.love platform and found similar results (Figure 2D, 2E). Overall, KCNQ1 showed aberrant expression profiling in pancarcinomas.

**Decreased expression of KCNQ1 in GC and its association with clinicopathological characteristics**

Using TCGA and GEO databases, we found reduced KCNQ1 mRNA expression in GC tissue versus normal stomach tissue samples (Figure
Low KCNQ1 expression and gastric cancer

3A), and the difference was even more significant in the matched tissue samples (Figure 3B), indicating under-expressed KCNQ1 in GC tissue samples versus normal counterparts. Meanwhile, HPA database showed that KCNQ1 protein was strongly expressed in normal gastric tissue (Figure 3C) while hardly expressed in cancer tissue (Figure 3D). The clinicopatholog-
Low KCNQ1 expression and gastric cancer

A

Moderate cytoplasmic and membranous positivity was observed in colorectal and thyroid cancers along with few melanomes, ovarian, stomach, pancreatic and liver cancers. Remaining cancers were weakly stained or negative.

B

Most tumors cells were negative. Cytoplasmic and membranous immunoreactivity of varying intensity was seen in colorectal cancers.

C

Expression of KCNQ1 across TCGA cancers (with tumor and normal samples)
Low KCNQ1 expression and gastric cancer

Figure 2. KCNQ1 expression in cancer tissues and tumor cells. A, B. KCNQ1 in different human cancer tissues and tumor cells in The Human Protein Atlas (TCGA). C. KCNQ1 in various cancers from TCGA data analyzed in TIMER. KCNQ1 presented low expression in breast invasive carcinoma (BRCA), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), and thyroid cancer (THCA), and high expression in cholangiocarcinoma (CHOL), kidney clear cell carcinoma (KIRC), colon adenocarcinoma (COAD), head and neck cancer (HNSC), kidney chromophobe (KICH), and rectum adenocarcinoma (READ). D, E. KCNQ1 mRNA in cancerous and normal tissues across UALCAN data and xiantao.love platform (ns, P≥0.05; *, P<0.05; **, P<0.01; ***, P<0.001).
Low KCNQ1 expression and gastric cancer

Figure 3. KCNQ1 is decreased in GC in the TCGA datasets. A. KCNQ1 mRNA in GC and normal gastric tissue specimens; B. KCNQ1 mRNA in GC and matched normal tissue specimens; C. KCNQ1 protein expression in gastric cancer tissue in HPA database; D. KCNQ1 protein expression in gastric normal tissue in HPA database. (*, P<0.05; **, P<0.01; ***, P<0.001).

Table 1. Association of KCNQ1 with the clinicopathological characteristics of gastric cancer patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total</th>
<th>KCNQ1 expression</th>
<th>χ²</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Low (n=187)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>High (n=188)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>2.313</td>
<td>0.128</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥65</td>
<td>106</td>
<td>121</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65</td>
<td>81</td>
<td>67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>0.811</td>
<td>0.368</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>116</td>
<td>125</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>71</td>
<td>63</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Invasion depth</td>
<td></td>
<td>12.631</td>
<td>0.006</td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>23</td>
<td>7</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>113</td>
<td>45</td>
<td>68</td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>148</td>
<td>86</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>91</td>
<td>49</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td>5.947</td>
<td>0.114</td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>111</td>
<td>46</td>
<td>65</td>
<td></td>
</tr>
<tr>
<td>N1</td>
<td>97</td>
<td>53</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>N2</td>
<td>85</td>
<td>41</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>N3</td>
<td>82</td>
<td>47</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>Distant metastasis</td>
<td></td>
<td>2.1</td>
<td>0.147</td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>330</td>
<td>160</td>
<td>170</td>
<td></td>
</tr>
<tr>
<td>M1</td>
<td>45</td>
<td>27</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td>8.750</td>
<td>0.033</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>54</td>
<td>20</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>111</td>
<td>49</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>160</td>
<td>88</td>
<td>72</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>50</td>
<td>30</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Differentiation grade</td>
<td></td>
<td>7.426</td>
<td>0.024</td>
<td></td>
</tr>
<tr>
<td>G1</td>
<td>18</td>
<td>13</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>G2</td>
<td>137</td>
<td>58</td>
<td>79</td>
<td></td>
</tr>
<tr>
<td>G3</td>
<td>220</td>
<td>116</td>
<td>104</td>
<td></td>
</tr>
<tr>
<td>Vital status</td>
<td></td>
<td>5.676</td>
<td>0.017</td>
<td></td>
</tr>
<tr>
<td>Alive</td>
<td>233</td>
<td>105</td>
<td>128</td>
<td></td>
</tr>
<tr>
<td>Dead</td>
<td>142</td>
<td>82</td>
<td>60</td>
<td></td>
</tr>
</tbody>
</table>

P<0.05, statistically significant.

cal characteristics of GC patients (age, sex, invasion depth, lymph node/distant metastasis, differentiation grade, tumor-node-metastasis (TNM) stage, and vital status) were collected from TCGA data through HOME for Researchers platform. A total of 375 GC patients (241 males and 134 females) were assigned to either a low or high KCNQ1 expression group based on the median KCNQ1 mRNA expression. There were 227 patients aged ≥65 years and 148 patients <65 years. As can be seen from Table 1, there was a significant connection between KCNQ1 expression and invasion depth (χ²=12.631, P=0.006), TNM stage (χ²=8.750, P=0.033), differentiation grade (χ²=7.426, P=0.024), and vital status (χ²=5.676, P=0.017) in GC patients. It is indicated that KCNQ1 may play a tumor-suppressing role in GC.
Low KCNQ1 expression and gastric cancer

KCNQ1 is associated with better prognosis in GC

The correlation of KCNQ1 with OS of GC patients was evaluated using KM plotter for GEO data and GEPIA for TCGA data, respectively. Upregulated KCNQ1 was strongly correlated with longer OS in both GEO data (HR: 0.71, P=0.00031) and TCGA data (HR: 0.69, P=0.021), as shown in Figure 4A and 4B. Additionally, using the Cox model, unvariable and multivariate analyses assessed the correlation of clinicopathological characteristics with OS. According to the univariate Cox model, age (P=0.005), invasion depth (P=0.011), LNM (P=0.003), distant metastasis (P=0.004), TNM stage (P<0.001), primary therapy outcome (P<0.001), and KCNQ1 expression (P=0.013) were factors significantly influencing the survival. Furthermore, T stage (P=0.041), primary therapy outcome (P<0.001), and KCNQ1 (P=0.024) were identified by the multivariate analysis as independent prognostic factors (Table 2). Overall, low expression KCNQ1 was an independent risk factor for poor prognosis in GC.

Table 2. Cox univariate and multivariate analyses of overall survival of gastric cancer patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Univariate</th>
<th>Multivariate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95% CI)</td>
<td>P</td>
</tr>
<tr>
<td>Age (≥65 vs. &lt;65)</td>
<td>1.620 (1.154-2.276)</td>
<td>0.005</td>
</tr>
<tr>
<td>Sex (female vs. male)</td>
<td>1.267 (0.891-1.804)</td>
<td>0.188</td>
</tr>
<tr>
<td>Invasion depth (T3/T4 vs. T1/T2)</td>
<td>1.719 (1.131-2.612)</td>
<td>0.011</td>
</tr>
<tr>
<td>LNM (N2/N3 vs. N0/N1)</td>
<td>1.650 (1.182-2.302)</td>
<td>0.003</td>
</tr>
<tr>
<td>Distant metastasis (M1 vs. M0)</td>
<td>2.254 (1.295-3.924)</td>
<td>0.004</td>
</tr>
<tr>
<td>KCNQ1</td>
<td>0.871 (0.781-0.971)</td>
<td>0.013</td>
</tr>
<tr>
<td>TNM stage (III-IV vs. I-II)</td>
<td>1.947 (1.358-2.793)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>H pylori infection (Yes vs. No)</td>
<td>0.650 (0.279-1.513)</td>
<td>0.317</td>
</tr>
<tr>
<td>PTO (SD/PR/CR vs. PD)</td>
<td>0.241 (0.165-0.352)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; HR, hazard ratio; LNM, lymph node metastasis; PTO, primary therapy outcome. P<0.05, statistically significant.
**Low KCNQ1 expression and gastric cancer**

To more comprehensively clarify the biological role of KCNQ1, we used Link-Finder to identify the CEI pattern of KCNQ1-related genes in TCGA-STAD that were differentially expressed in GC between high and low KCNQ1 expression datasets. The results revealed 13017 genes (in dark red) and 7208 genes (in dark green) that were positively and negatively associated with KCNQ1, respectively (Figure 5A). The top 50 genes in STAD are presented in heat maps (Figure 5B, 5C). Based on GO term annotations, the co-expressed genes of KCNQ1 were concentrated in various biological processes, such as digestion, carbohydrate derivative transport, peroxisome organization, execution phase of apoptosis, tricarboxylic acid metabolism, carbohydrate catabolism, small molecule catabolism, cofactor biosynthesis, and cellular aldehyde metabolism (Figure 5D). According to KEGG pathway analysis, KCNQ1 enrichment was primarily found in peroxisome organization, carbon metabolism, citrate cycle (TCA cycle), fatty acid degradation, fructose and mannose metabolism, glycolysis/gluconeogenesis, sphingolipid metabolism, aminoacyl-tRNA biosynthesis, and sulfur metabolism (Figure 5E-G). The above results suggest the extensive influence of KCNQ1 expression networks on the outcome and metabolic process of GC.

**KCNQ1 PPI analysis and spatial structure composition**

We utilized STRING to identify the PPI networks of KCNQ1 protein, and formed a core network comprised of 11 nodes and 23 edges, with an average node degree of 4.18 and a local clustering coefficient of 0.859 (P=0.0005; Figure 6A). The proteins interacted with KCNQ1 were AKAP9, KCNE1, CALM3, KCNE2, KCNE3, CALM2, KCNH2, KCNJ2, KCNE4 and ADCY9. Of these, AKAP9, KCNE4, and CALM2 were at the core of the KCNQ1 protein network. These genes were primarily implicated in potassium ion export and cyclic-nucleotide signaling, and function as activators of adenylate cyclase. All of the above pathological processes play critical roles in the metabolic process of GC cells.

Using Swiss Model’s online web-based client, the 3D structure of the KCNQ1 protein was modeled and validated. The original (wild-type) model of the KCNQ1 protein is shown in Figure 6B, where blue and red colors represent the coiled peptide chain from the protein’s N-to-C-terminus. This chain by itself has no function but can form a heterotetramer with CaM and has VGPC activity [22] (Figure 6C). KCNQ1 can form heteromultimers with CaM and KCNE3, inducing voltage-dependent currents through the rapid activation and slow inactivation of potassium-selective outward currents (Figure 6D).

**Discussion**

Expressed in multiple tissues throughout the body, KCNQ1 potassium channels can modulate many key physiological functions. Due to its tissue-specific imprinting, KCNQ1 is essential in various tissues, including the heart, inner ear, stomach and colon [11, 12]. The differential KCNQ1 mRNA levels also play a vital part in pan-cancer progression. To better clarify the role of KCNQ1 in humans, we comprehensively examined KCNQ1 in normal human tissues, organs and cell lines based on the HPA data. We confirmed the differences in KCNQ1 mRNA levels between 33 different human tumors and their corresponding adjacent counterparts based on HPA, TIMER and UALCAN databases.

Previously, the expression pattern of KCNQ1 was measured in many tissues and found to be enhanced in adrenal gland, ductus deferens and seminal vesicle but had low brain region specificity in human. Meanwhile, KCNQ1 mRNA expression was found to be specifically enhanced in undifferentiated cells and enterocytes. Moreover, among cell lines expressing KCNQ1, KCNQ1 mRNA was observed to be particularly enhanced in HMC-1, RPMI-8226, OE19, U-937, and U-266/70. We also used three different databases to perform analysis of differential expression in varying tumors and all the results revealed the aberrant expression of KCNQ1 in pan-cancers. Therefore, KCNQ1 expression in GC was further assessed using TCGA and GEO databases and was determined to be lower in GC tissue samples versus normal counterparts.

Since this study was primarily intended to investigate the role of KCNQ1 in GC, we further analyzed the association of KCNQ1 with the clinicopathological characteristics of patients using TCGA. KCNQ1 was determined to be significantly associated with invasion depth, TNM...
Low KCNQ1 expression and gastric cancer

A

B

C

D

E

F

G

Low KCNQ1 expression and gastric cancer

Figure 5. KCNQ1 co-expressed genes in GC from LinkedOmics. A. Significantly KCNQ1-associated genes in STAD cohort distinguished by the Pearson test. B, C. Heatmap of the top 50 genes most positively (red) and negatively (blue) related to KCNQ1. D-G. GO annotations and KEGG pathway analysis of KCNQ1 in STAD cohort.

Figure 6. KCNQ1 protein-protein interaction (PPI) analysis and spatial structure composition. A. The core KCNQ1-associated PPI networks in gastric cancer, consisting 11 nodes (represent proteins) and 23 edges (represent interactions between proteins in the network) with a mean node degree of 4, were built by STRING database. KCNQ1, Potassium voltage-gated channel subfamily KQT member 1; AKAP9, A-kinase anchor protein 9; KCNE1, Potassium voltage-gated channel subfamily E member 1; CALM3, Calmodulin-1; Calmodulin 3 (phosphorylase kinase, delta); KCNE2, Potassium voltage-gated channel subfamily E member 2; KCNE3, Potassium voltage-gated channel subfamily E member 3; CALM2, Calmodulin 2 (phosphorylase kinase, delta); KCNH2 Potassium voltage-gated channel subfamily H member 2; KCNJ2, Inward rectifier potassium channel 2; KCNE4, Potassium voltage-gated channel subfamily E member 4; ADCY9, Adenylate cyclase type 9; B. The original model of KCNQ1 protein; C. Human KCNQ1 protein in complex with CaM; D. Structure of human KCNQ1-KCNE3-CaM complex.

stage, differentiation grade, and vital status in GC patients, suggesting a possible inhibitory role of KCNQ1 in GC progression. Additionally, we also found that higher level of KCNQ1 was significantly related to longer OS. Multivariate analysis further revealed that T stage, primary therapy outcome and KCNQ1 expression were independent prognostic factors for OS. Overall, the under-expressed KCNQ1 gene in GC is associated with unfavorable outcomes and malignant phenotypes in GC patients [23]. KCNQ1 acts as an anti-oncogene in inhibiting tumor progression through modulating metabolic process in GC. Studies have shown that people carrying the KCNQ1 germline mutation can develop a range of disorders, including hearing loss, gastrin elevation, gastric hyperplasia and, in some cases, tumors [19, 24, 25]. Recently, KCNQ1 has been suggested to play a critical part in colorectal carcinoma cell growth, EMT, invasion, and tumorigenesis, with an association with adverse disease-free survival via regulating the Wnt/β-catenin axis [26, 27]. In addition, KCNQ1 functions as an anti-oncogene in mouse and human carcinomas of the digestive tract [18]. Such phenotypes have also
been modeled in KCNQ1 knockout mice. As a result, the animals developed inner ear defects, chronic gastritis, imbalances, as well as gastric hyperplasia and metaplasia [28], demonstrating the relationship between KCNQ1 and the carcinogenesis and progression of GC.

Subsequently, we explored the CEI network of KCNQ1 in GC using the LinkedOmics portal to test KCNQ1's biological role in GC. KCNQ1 is a protein coding gene that can generate heteromultimers with KCNE1 and KCNE3, two potassium channel proteins [29]. Its role in human cancers has also been established [30]. This study demonstrated the extensive impact of KCNQ1 expression networks on the metabolic processes and outcomes of GC, including tricarboxylic acid metabolism, digestion, carbohydrate catabolism, peroxisome, carbon metabolism, and the citrate cycle (TCA cycle), as validated by GO term annotation and KEGG pathway analyses. These findings provide insight into the potential anti-oncogene role of KCNQ1 in GC cells. To explore the function of KCNQ1, we constructed its PPI networks and homologous function model, and found that KCNE3 and CaM were the functional subunits of KCNQ1. However, the pathway mechanisms and homology modeling involved still need further in vitro and in vivo validation.

Several limitations of this study remain to be noted. While KCNQ1 has been suggested to be crucial in GC and a candidate therapeutic target, the conclusions are obtained by analyzing data from public databases without validation using experiments. In the present study, KCNQ1 mRNA expression was found to be associated with the survival in GC patients, and KCNQ1 protein levels were correlated with OS. But based on the conflicting results of ID1, KCNQ1 has been suggested to be essential in GC onset and development. Hence, it is necessary to further investigate its specific role in GC tumorigenesis and progression to gain a better understanding of the underlying molecular mechanisms of KCNQ1.

Conclusion

This study is the first to reveal the prognostic implications of the expression patterns and biological role of KCNQ1 in GC and its promising prognostic significance, contributing to a better understanding of the mechanisms underlying GC recurrence and metastasis. KCNQ1 was downregulated in GC tissue, and low KCNQ1 expression is associated with adverse prognosis. KCNQ1 channels are expected to be a feasible prognostic index and a candidate target for GC therapy.

Acknowledgements

I would like to express my gratitude to xiantao.love platform (https://www.xiantao.love/). This study was funded by the Second Affiliated Hospital of Air Force Medical University Recruitment Assistance Scheme (2021SHRCC055) and the program for XKPT Construction of Tangdu Hospital (2020XKPT013).

Disclosure of conflict of interest

None.

Address correspondence to: Wei Xin and Guoqiang Bao, Department of General Surgery, The Second Affiliated Hospital of Air Force Medical University, Xi’an 710038, Shaanxi, China. Tel: +86-13679280082; E-mail: wy2442770420@126.com (WX); Tel: +86-13891430409; E-mail: guoqiang@fmmu.edu.cn (GQB)

References


Low KCNQ1 expression and gastric cancer


